Skip to content
Homepage
Author:
Repair Biotechnologies, Inc.
Posted Date:
May 21, 2026
Repair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial Hypercholesterolemia
Repair Biotechnologies, Inc.
May 21, 2026
